Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of barriers associated with implementing cellular therapies in solid tumors. Unlike hematological malignancies which can be targeted with CD19, a receptor exclusively found in solid tumors remains to be elucidated. Dr Schlechter additionally highlights T cell antigen coupler (TAC) T cells in gastrointestinal malignancies under development, which can reduce the risk of developing off-target adverse events. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.